文献速递肥胖与代谢综合征糖尿病

轻至中度高甘油三酯血症患者有效且可改变疾病进程的临床干预策略

Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-12-16

血浆甘油三酯浓度测量简便、经济且准确,升高时是有信息量的疾病标志物,可识别常伴有代谢、炎症和致动脉粥样硬化危险因素的个体。轻至中度高甘油三酯血症患者常未被识别为代谢综合征,也未接受可改变疾病进程的治疗。治疗包括生活方式干预、降低LDL以积极治疗升高的含载脂蛋白B颗粒、优化降压治疗、高风险者使用二十碳五烯酸乙酯、糖尿病患者优先使用心血管保护性降糖药及抗血栓治疗。

要点

  • 轻至中度高甘油三酯血症提示代谢、炎症和致动脉粥样硬化风险因素聚集。
  • 治疗包括生活方式干预和积极降低LDL以治疗升高的含载脂蛋白B颗粒。
  • 高风险者尤其是已确诊动脉粥样硬化性心血管疾病且经适当降LDL治疗后仍有残余高甘油三酯血症者可使用二十碳五烯酸乙酯。

核心结论

  • 轻至中度高甘油三酯血症患者常未被识别为代谢综合征,也常未接受可改变疾病进程的确定性治疗。
  • 治疗应包括生活方式干预、降低LDL以积极治疗升高的含载脂蛋白B颗粒、优化降压治疗、高风险者使用二十碳五烯酸乙酯、糖尿病患者优先使用心血管保护性降糖药及抗血栓治疗。

研究设计与样本

  • 原文未报告研究设计。

主要发现

  • 血浆甘油三酯浓度测量简便、经济且准确,升高时是有信息量的疾病标志物,可识别常伴有代谢、炎症和致动脉粥样硬化危险因素的个体。
  • 筛查血脂发现轻至中度高甘油三酯血症的个体不一定被识别为具有代谢综合征特征,且常未接受可改变疾病进程的确定性治疗。

关键数值与推荐

  • 治疗包括生活方式干预。
  • 治疗包括降低LDL以积极治疗升高的含载脂蛋白B颗粒。
  • 治疗包括对代谢综合征个体使用具有最佳治疗特征的降压治疗。
  • 对高风险个体,尤其是已确诊动脉粥样硬化性心血管疾病且经适当降LDL治疗后仍有残余高甘油三酯血症者,使用二十碳五烯酸乙酯。
  • 对糖尿病患者优先使用心血管保护性降糖治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasma triglyceride concentration is easily, inexpensively, and accurately measured, and when elevated is a highly informative disease marker that identifies individuals who frequently have a host of underlying metabolic, inflammatory, and atherogenic risk factors. Although this concept aligns with much that has been discussed regarding the metabolic syndrome, individuals identified with mild-to-moderate hypertriglyceridaemia on a screening lipid profile are not necessarily recognised as having features of the metabolic syndrome and frequently do not receive definitive, meaningful, disease-modifying therapy. This treatment would include (1) lifestyle modification; (2) LDL-lowering therapies to aggressively treat elevated apolipoprotein B-containing particles; (3) antihypertensive therapies that have optimal therapeutic profiles for those individuals with metabolic syndrome; (4) icosapent ethyl for those individuals at high risk, particularly patients with established atherosclerotic cardiovascular disease who have residual hypertriglyceridaemia despite treatment with appropriate LDL-lowering therapies; (5) preferential use of cardiovascular protective diabetes therapies, in individuals with diabetes; and (6) antithrombotic therapies for secondary prevention of atherosclerotic cardiovascular disease in the context of high vascular disease risk and diabetes. Several emerging therapies, such as novel weight reducing, anti-inflammatory, lipid-modifying therapies, and therapies targeting the progression of non-alcoholic fatty liver disease, could also soon enter the clinical arena for patients with mild-to-moderate hypertriglyceridaemia and associated metabolic syndrome.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Lewis GF, Hegele RA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes Endocrinol. 2021. PMID: 34922644. doi:10.1016/S2213-8587(21)00284-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。